A new type 2 diabetes drug by Johnson & Johnson, called Canagliflozin, has been approved by the U.S. Food and Drug Administration (FDA) committee with a vote of 10 to 5.
The Endocrinologic and Metabolic Drug Advisory Committee by a majority vote recommended that the FDA approve canagliflozin because “it proved effective at lowering blood sugar in patients with diabetes, though some panelists had lingering concerns about its potential to cause cardiovascular problems and recommended longer term follow-up,” according to Reuters.
Canagliflozin, trade name Invokana, will have to receive further approval this year by the FDA. If it is approved to hit the market, the brand-new diabetes drug will be the first of its type available in the U.S.
According to Reuters, canagliflozin “is a member of a fresh class of diabetes drugs known as sodium-glucose co-transporter-2 (SGLT2) inhibitors which lower blood sugar by blocking reabsorption of glucose by the kidney and increasing the excretion of glucose in urine.”
Type 2 diabetes patients have kidneys that reabsorb a larger than normal amount of glucose back into their bodies.
“We are pleased with the positive recommendation from the committee and look forward to working with the FDA to bring this important new therapy to patients in the U.S. to help them manage their type 2 diabetes,” said Dr. Peter Stein, head of the Metabolism Development and Diabetes Disease Area departments at Janssen Research and Development, the Johnson & Johnson R&D company that developed the drug. “Today’s outcome represents an important step toward achieving that goal.”